Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Accounts Receivables
Zealand Pharma A/S
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Accounts Receivables
kr193.6m
|
CAGR 3-Years
38%
|
CAGR 5-Years
204%
|
CAGR 10-Years
23%
|
|
|
Genmab A/S
CSE:GMAB
|
Accounts Receivables
kr6.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
51%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Accounts Receivables
€166.3m
|
CAGR 3-Years
323%
|
CAGR 5-Years
191%
|
CAGR 10-Years
62%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Accounts Receivables
kr1.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
93%
|
CAGR 10-Years
20%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Accounts Receivables
kr8.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Accounts Receivables
kr15m
|
CAGR 3-Years
61%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Accounts Receivables?
Accounts Receivables
193.6m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Accounts Receivables amounts to 193.6m DKK.
What is Zealand Pharma A/S's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
23%
Over the last year, the Accounts Receivables growth was 19 179%. The average annual Accounts Receivables growth rates for Zealand Pharma A/S have been 38% over the past three years , 204% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet